Tonic levels of angiotensin II reduce tonic levels of vascular nitric oxide even in salt-replete man

What Was Tested

The paper reports a study of Angiotensin II, published as a randomized controlled trial.

Who Took Part

The study group was 24 volunteers.

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the volunteers nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

Brachial artery endothelial function was assessed by bilateral venous occlusion plethysmography, measuring the response to intra-arterial infusions of the endothelial-dependent and endothelial-independent vasodilators, acetylcholine and sodium nitroprusside respectively and the endothelial-dependent vasoconstrictor NG-monomethyl-L-arginine.

What Was Measured

The subject headings attached to it are Acetylcholine, Angiotensin II, Antihypertensive Agents, Blood Pressure, Brachial Artery, Enzyme Inhibitors and Losartan.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 24 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2004 (Journal of the renin-angiotensin-aldosterone system : JRAAS), a journal based in England.

More context: the Angiotensin II compound page, all human trials.